These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
159 related items for PubMed ID: 22419099
1. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Tsutsumi Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Imamura M. Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099 [No Abstract] [Full Text] [Related]
2. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Brugger W, Ghielmini M. Oncologist; 2013 May; 18(8):954-64. PubMed ID: 23900001 [Abstract] [Full Text] [Related]
3. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M, German Low Grade Lymphoma Study Group. Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757 [Abstract] [Full Text] [Related]
4. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. Blood; 2011 Mar 10; 117(10):2807-12. PubMed ID: 21239695 [Abstract] [Full Text] [Related]
5. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Rummel MJ, Mitrou PS, Hoelzer D. Semin Oncol; 2002 Aug 10; 29(4 Suppl 13):27-32. PubMed ID: 12170430 [Abstract] [Full Text] [Related]
6. Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy. Herishanu Y, Katz BZ. Blood; 2015 Feb 05; 125(6):1047. PubMed ID: 25802907 [No Abstract] [Full Text] [Related]
7. The emerging role of bendamustine in follicular lymphoma. Friedberg JW. Leuk Lymphoma; 2009 Mar 05; 50(3):317-8. PubMed ID: 19347722 [No Abstract] [Full Text] [Related]
8. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Darwish M, Burke JM, Hellriegel E, Robertson P, Phillips L, Ludwig E, Munteanu MC, Bond M. Cancer Chemother Pharmacol; 2014 Jun 05; 73(6):1119-27. PubMed ID: 24677018 [Abstract] [Full Text] [Related]
9. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Koo YX, Tan DS, Tan IB, Tao M, Lim ST. Ann Intern Med; 2009 May 05; 150(9):655-6. PubMed ID: 19414854 [No Abstract] [Full Text] [Related]
10. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Garnock-Jones KP. Drugs; 2010 Sep 10; 70(13):1703-18. PubMed ID: 20731477 [Abstract] [Full Text] [Related]
11. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. Ann Oncol; 2015 Aug 10; 26(8):1667-77. PubMed ID: 25712458 [Abstract] [Full Text] [Related]
12. Resolution of granuloma annulare following treatment with bendamustine and rituximab in a patient with follicular lymphoma: a serendipitous finding. Shah BK, Hewett Y, Peterson A, Tretheway D. J Postgrad Med; 2014 Aug 10; 60(4):406-8. PubMed ID: 25370553 [Abstract] [Full Text] [Related]
13. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Ann Hematol; 2011 Oct 10; 90(10):1219-23. PubMed ID: 21520001 [Abstract] [Full Text] [Related]
14. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Leukemia; 2015 Aug 10; 29(8):1695-701. PubMed ID: 25765545 [Abstract] [Full Text] [Related]
15. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma. Sanchez-Gonzalez B, Gimeno E, Garcia-Pallarols F, Ancochea A, Salar A. Leuk Lymphoma; 2014 Oct 10; 55(10):2384-6. PubMed ID: 24601815 [No Abstract] [Full Text] [Related]
16. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Clin Lymphoma Myeloma Leuk; 2010 Dec 10; 10(6):452-7. PubMed ID: 21189660 [Abstract] [Full Text] [Related]
17. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. Gueli A, Gottardi D, Hu H, Ricca I, De Crescenzo A, Tarella C. Blood Transfus; 2013 Apr 10; 11(2):311-4. PubMed ID: 23399352 [No Abstract] [Full Text] [Related]
18. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Burke JM, van der Jagt RH, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Simpson D, Craig M, Kolibaba K, Issa S, Munteanu M, Victor TW, Flinn IW. Clin Lymphoma Myeloma Leuk; 2016 Apr 10; 16(4):182-190.e1. PubMed ID: 26875824 [Abstract] [Full Text] [Related]